Four Sessions Highlighted Data from Recent CooperVision-Sponsored and Independent Research
TOKYO, Oct. 17 2019—Eye care professionals and researchers from around the world gathered at the 17th International Myopia Conference in Tokyo from September 12 – 15, 2019. Through educational talks and scientific presentations, CooperVision shared research findings and learnings about progressive pediatric myopia, its growing prevalence and severity, and how to reach better outcomes for myopic children.
CooperVision shared insights from its learnings from the last decade in myopia management. Stuart Cockerill, Paul Chamberlain and James Gardner of CooperVision discussed the journey the company has taken as it developed the MiSight® 1 day soft contact lens1, observations from its landmark multi-year clinical study, and how the company will continue to take a global leadership position in tackling the epidemic. During the session, Chamberlain also summarized the most recent five-year clinical study data, which found progression rates among the original control group—after already showing a dramatic reduction in year four following refitting—matched the children who had been wearing MiSight® 1 day for the entire duration of the study in spherical equivalent refractive error (0.17D) and axial length (0.07mm) during year five2. Vision performance also remained excellent for both groups, with visual acuity of better than 6/6 at every scheduled appointment2.
Paul Chamberlain, Director of Research Programs for CooperVision, also presented a scientific paper on measured and predicted axial length changes during the MiSight® 1 day clinical study, which is now in its sixth year. The study is the longest continuous soft contact lens study for myopia management.
Independent researchers presented data from two recent CooperVision-sponsored studies. Maria Liu, OD, PhD, FAAO, Assistant Professor of Clinical Optometry at the University of California, Berkeley, presented “A Pilot Study Comparing CRT Orthokeratology Lenses with Two Different Treatment Zone Sizes”. Viswanathan Ramasubramanian, a research associate at the Indiana University School of Optometry, also presented a poster titled, “Do multi-zone contact lenses decrease hyperopic defocus or increase myopic defocus or both?”
“The surge of childhood myopia has left the eye care industry with many questions. As more research is conducted, we are beginning to understand new ways to decelerate the condition’s progression,” said Juan Carlos Aragon, President of CooperVision Specialty EyeCare. “CooperVision’s commitment is demonstrated in part through the MiSight® 1 day lens, which is clinically proven to slow myopia progression in children. We have also made several strategic acquisitions over the past few years in the specialty segment, including Paragon Vision Sciences and Procornea. These give us additional paths to explore myopia management breakthroughs.”
# # #
1 MiSight® 1 day contact lenses are currently available for sale in Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Belgium, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® 1 day is not approved in the United States or Japan.
2 Chamberlain P, Logan N, Jones D, Gonzalez-Meijome J, Saw S-M, Young G. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens: 5-year results (2019 BCLA Clinical Conference & Exhibition)
CooperVision, a unit of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
Mike McDougall, APR, Fellow PRSA
McDougall Communications for CooperVision, Inc.
email@example.com or +1-585-545-1815 (mobile)